RxDoctor Payments Data

Michael Heder, DO

Family Medicine · Heber, UTNPI 1629563572

Payments from drug & device makers

$848in general payments, 2019–2025

Across 45 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$190
  • Lilly USA, LLC$152
  • Medtronic$108
  • Inspire Medical Systems, Inc.$70
  • Exact Sciences$56
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44
  • plus $228 from 10 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$500

What the payments were for

  • Food & beverage$848100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$848 in reported general payments places this provider in the 60th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$64,382
Medicare patients
195
Services billed
1,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$34,570
EliquisApixaban29$22,879
Soliqua 100-33Insulin Glargine/Lixisenatide15$21,994
TrulicityDulaglutide12$11,473
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,068
Gabapentin181$2,989
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,221
Omeprazole103$1,631
Celecoxib39$1,618
Atorvastatin Calcium126$1,495
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate11$1,019
Duloxetine Hcl27$998
Levothyroxine Sodium126$986
Insulin Lispro Kwikpen U-100Insulin Lispro15$946
Pantoprazole Sodium51$937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$152$46,04439 claims
PfizerEliquis$31$22,87929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 928 family medicine providers in Utah.

Other family medicine in Heber

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →